{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SMARCA4+Gene+Mutation", "query": { "condition": "SMARCA4 Gene Mutation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T03:06:34.919Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05639751", "title": "PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Non-small Cell Lung Cancers", "SMARCA4 Gene Mutation" ], "interventions": [ { "name": "PRT3789", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2023-05-02", "completion_date": "2025-10-01", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-05-22T03:06:34.919Z", "location_count": 20, "location_summary": "Sacramento, California • Santa Monica, California • New Haven, Connecticut + 13 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Celebration", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05639751" }, { "nct_id": "NCT06560645", "title": "A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Non-small Cell Lung Carcinoma", "SMARCA4 Mutation", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastric Squamous Cell Carcinoma", "Gastroesophageal Junction Adenocarcinoma", "Gastroesophageal Junction Squamous Cell Carcinoma" ], "interventions": [ { "name": "PRT7732", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2024-11-04", "completion_date": "2026-01-28", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-05-22T03:06:34.919Z", "location_count": 11, "location_summary": "San Francisco, California • Detroit, Michigan • New York, New York + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06560645" }, { "nct_id": "NCT07284186", "title": "First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastric Squamous Cell Carcinoma", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Metastatic Solid Tumor", "Non-Small Cell Lung Carcinoma", "Esophageal Adenocarcinoma", "SMARCA4 Mutation", "Gastroesophageal Junction Squamous Cell Carcinoma", "Advanced Solid Tumor" ], "interventions": [ { "name": "PLX-61639", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Plexium, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2025-12-01", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T03:06:34.919Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Duarte, California • Orange, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07284186" }, { "nct_id": "NCT04257045", "title": "Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Carcinoma", "Deleterious CDH1 Gene Mutation", "Deleterious DICER1 Gene Mutation", "Deleterious SMARCA4 Gene Mutation", "Deleterious STK11 Gene Mutation", "Endometrial Carcinoma", "Fallopian Tube Carcinoma", "Ovarian Carcinoma", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Interview", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2019-08-21", "completion_date": "2024-07-09", "has_results": false, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-05-22T03:06:34.919Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Houston, Texas", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04257045" }, { "nct_id": "NCT01238250", "title": "Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "16P11.2 Deletion Syndrome", "16p11.2 Duplications", "1Q21.1 Deletion", "1Q21.1 Microduplication Syndrome (Disorder)", "ACTL6B", "ADNP", "AHDC1", "ANK2", "ANKRD11", "ARID1B", "ASH1L", "BCL11A", "CHAMP1", "CHD2", "CHD8", "CSNK2A1", "CTBP1", "CTNNB1 Gene Mutation", "CUL3", "DDX3X", "DNMT3A", "DSCAM", "DYRK1A", "FOXP1", "GRIN2A", "GRIN2B", "HIVEP2-Related Intellectual Disability", "HNRNPH2", "KATNAL2", "KDM5B", "KDM6B", "KMT2C Gene Mutation", "KMT2E", "KMT5B", "MBD5", "MED13L", "PACS1", "PPP2R5D-Related Intellectual Disability", "PTCHD1", "REST", "SCN2A Encephalopathy", "SETBP1 Gene Mutation", "SETD5", "SMARCA4 Gene Mutation", "SMARCC2", "STXBP1 Encephalopathy With Epilepsy", "SYNGAP1-Related Intellectual Disability", "TBR1", "ARHGEF9", "HNRNPU", "PPP3CA", "PPP2R1A", "SLC6A1", "2p16.3 Deletions", "5q35 Deletions", "5q35 Duplications", "7q11.23 Duplications", "15Q13.3 Deletion Syndrome", "16p11.2 Triplications", "16P12.2 Microdeletion", "16P13.11 Microdeletion Syndrome (Disorder)", "17Q12 Microdeletion Syndrome (Disorder)", "17Q12 Duplication Syndrome", "17Q21.31 Deletion Syndrome", "17q21.3 Duplications", "ACTB", "ADSL", "AFF2", "ALDH5A1", "ANK3", "ARX", "ATRX Gene Mutation", "AUTS2 Syndrome", "BCKDK", "BRSK2", "CACNA1C", "CAPRIN1", "CASK", "CASZ1", "CHD3", "CIC", "CNOT3", "CREBBP Gene Mutation", "CSDE1", "CTCF", "DEAF1", "DHCR7", "DLG4", "EBF3", "EHMT1", "EP300 Gene Mutation", "GIGYF1", "GRIN1", "GRIN2D", "IQSEC2-Related Syndromic Intellectual Disability", "IRF2BPL", "KANSL1", "KCNB1", "KDM3B", "NEXMIF", "KMT2A", "MBOAT7", "MEIS2", "MYT1L", "NAA15", "NBEA", "NCKAP1", "NIPBL", "NLGN2", "NLGN3", "NLGN4X", "NR4A2", "NRXN1", "NRXN2", "NSD1 Gene Mutation", "PHF21A", "PHF3", "PHIP", "POMGNT1", "PSMD12", "RELN", "RERE", "RFX3", "RIMS1", "RORB", "SCN1A", "SETD2 Gene Mutation", "SHANK2", "SIN3A", "SLC9A6", "SON", "SOX5", "SPAST", "SRCAP", "TAOK1", "TANC2", "TCF20", "TLK2", "TRIO", "TRIP12", "UPF3B", "USP9X", "VPS13B", "WAC", "WDFY3", "ZBTB20", "ZNF292", "ZNF462", "2Q37 Deletion Syndrome", "9q34 Duplications", "15q15 Deletions", "15Q24 Deletion", "NR3C2", "SYNCRIP", "2q34 Duplication", "2q37.3 Deletion", "6q16 Deletion", "15q11.2 BP1-BP2 Deletion", "16p13.3 Deletion", "17Q11.2 Microduplication Syndrome (Disorder)", "17p13.3", "Xq28 Duplication", "CLCN4", "CSNK2B", "DYNC1H1", "EIF3F", "GNB1", "MED13", "MEF2C", "RALGAPB", "SCN1B", "YY1", "Xp11.22 Duplication", "PACS2", "MAOA", "MAOB", "HNRNPC", "HNRNPD", "HNRNPK", "HNRNPR", "HNRNPUL2", "5P Deletion Syndrome", "TCF7L2 Gene Mutation", "HECW2" ], "interventions": [], "intervention_types": [], "sponsor": "Simons Searchlight", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100000, "start_date": "2010-10", "completion_date": "2050-10", "has_results": false, "last_update_posted_date": "2025-06-06", "last_synced_at": "2026-05-22T03:06:34.919Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Lewisburg, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Lewisburg", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01238250" }, { "nct_id": "NCT03213665", "title": "Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Low Grade Glioma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Hodgkin Lymphoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Refractory Hodgkin Lymphoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Soft Tissue Sarcoma", "Rhabdoid Tumor", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Wilms Tumor" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 20, "start_date": "2017-11-13", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T03:06:34.919Z", "location_count": 115, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03213665" }, { "nct_id": "NCT06682806", "title": "A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Esophageal Cancer", "Metastatic Solid Tumor", "Non-small Cell Lung Cancers", "SMARCA4 Gene Mutation" ], "interventions": [ { "name": "PRT3789", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2025-06-03", "completion_date": "2026-01-23", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-05-22T03:06:34.919Z", "location_count": 6, "location_summary": "West Palm Beach, Florida • Detroit, Michigan • Hackensack, New Jersey + 2 more", "locations": [ { "city": "West Palm Beach", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06682806" } ] }